Ingo Ringshausen

2.9k total citations
47 papers, 1.8k citations indexed

About

Ingo Ringshausen is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Ingo Ringshausen has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 23 papers in Molecular Biology and 18 papers in Pathology and Forensic Medicine. Recurrent topics in Ingo Ringshausen's work include Chronic Lymphocytic Leukemia Research (31 papers), Lymphoma Diagnosis and Treatment (18 papers) and Immunodeficiency and Autoimmune Disorders (8 papers). Ingo Ringshausen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (31 papers), Lymphoma Diagnosis and Treatment (18 papers) and Immunodeficiency and Autoimmune Disorders (8 papers). Ingo Ringshausen collaborates with scholars based in Germany, United Kingdom and United States. Ingo Ringshausen's co-authors include Christian Peschel, Thomas Decker, Andrew J. Finch, Gérard I. Evan, Lamorna Brown Swigart, Christian Bogner, Folker Schneller, Madlene Oelsner, Susanne Hipp and Maria A. Christophorou and has published in prestigious journals such as Nature, Nature Communications and Blood.

In The Last Decade

Ingo Ringshausen

43 papers receiving 1.8k citations

Peers

Countries citing papers authored by Ingo Ringshausen

Since Specialization

Citations

This map shows the geographic impact of Ingo Ringshausen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo Ringshausen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo Ringshausen more than expected).

Fields of papers citing papers by Ingo Ringshausen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingo Ringshausen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo Ringshausen. The network helps show where Ingo Ringshausen may publish in the future.

Co-authorship network of co-authors of Ingo Ringshausen

This figure shows the co-authorship network connecting the top 25 collaborators of Ingo Ringshausen. A scholar is included among the top collaborators of Ingo Ringshausen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingo Ringshausen. Ingo Ringshausen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia 2025 ·British Journal of Haematology ·Renata Walewska, Toby A. Eyre, Adrian Bloor, (unknown), Sunil Iyengar, (unknown), Helen Marr, Nicolás Martínez‐Calle, Alison M. McCaig, (unknown), Talha Munir, Helen Parry, Nilima Parry‐Jones, Andrew R. Pettitt, John C. Riches, Ingo Ringshausen, Anna Schuh, Piers Patten	0
2	Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial 2024 ·BMC Cancer ·Graham McIlroy, Siân Lax, Charlotte Gaskell, Aimee Jackson, (unknown), (unknown), Sonia Fox, (unknown), Jessica Okosun, Sally F. Barrington, Ingo Ringshausen, Alan G. Ramsay, Maria Calaminici, Kim Linton, Mark Bishton	1
3	ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV–unmutated chronic lymphocytic leukemia 2023 ·Blood Advances ·(unknown), Vijitha Sathiaseelan, (unknown), Valar Nila Roamio Franklin, Constanze A. Jakwerth, Clive S. D’Santos, Ingo Ringshausen	5
4	Robust CRISPR-Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells 2023 ·HemaSphere ·(unknown), (unknown), (unknown), Marta Kulis, Dolors Colomer, Elı́as Campo, Ingo Ringshausen, José I. Martı́n-Subero, Alba Maiqués-Díaz	5
5	Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape 2022 ·Nature Communications ·(unknown), Alba Maiqués-Díaz, (unknown), Elena Hartmann, Johannes Bloehdorn, A. P. Moore, (unknown), Junyan Lu, Valar Nila Roamio Franklin, (unknown), (unknown), Andreas Rosenwald, Stephan Stilgenbauer, Thorsten Zenz, Irina Mohorianu, Clive S. D’Santos, Silvia Deaglio, Daniel J. Hodson, José I. Martı́n-Subero, Ingo Ringshausen	19
6	Transforming Growth Factor-Beta Orchestrates Tumour and Bystander Cells in B-Cell Non-Hodgkin Lymphoma 2022 ·Cancers ·(unknown), Ingo Ringshausen	14
7	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia 2021 ·Nature Communications ·Veronika Ecker, (unknown), (unknown), (unknown), (unknown), Thomas Engleitner, Ingo Ringshausen, (unknown), Manfred Jücker, S. Wänninger, Thorsten Zenz, Clemens‐Martin Wendtner, Katrin Manske, Katja Steiger, Roland Rad, Markus Müschen, Jürgen Ruland, Maike Buchner	50
8	ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia 2021 ·Blood ·(unknown), Vijitha Sathiaseelan, A. P. Moore, Shengjiang Tan, (unknown), Valar Nila Roamio Franklin, (unknown), Constanze A. Jakwerth, Sandra B. Hake, Alan J. Warren, Irina Mohorianu, Clive S. D’Santos, Ingo Ringshausen	16
9	Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance 2020 ·Science Translational Medicine ·Eugene Park, (unknown), A. P. Moore, (unknown), Antonella Santoro, Joseph R. Boyd, Hilde Schjerven, Veronika Ecker, Maike Buchner, James C. Williamson, Paul J. Lehner, Luca Gasparoli, Owen Williams, Johannes Bloehdorn, Stephan Stilgenbauer, Michael Leitges, Alexander Egle, Marc Schmidt‐Supprian, Seth Frietze, Ingo Ringshausen	22
10	Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation 2020 ·Blood Advances ·Antonella Santoro, (unknown), (unknown), Emily F. Calderbank, Alison Wray, E. Joanna Baxter, Anna L. Godfrey, Elisa Laurenti, Ingo Ringshausen	1
11	Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome 2017 ·Scientific Reports ·Kathleen J. Till, Jeffrey C. Allen, (unknown), Ke Lin, David Allsup, Lynn Cawkwell, Alison R. Bentley, Ingo Ringshausen, (unknown), Andrew R. Pettitt, Nagesh Kalakonda, Joseph R. Slupsky	13
12	Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 2011 ·Leukemia ·Stephan M. Huber, Madlene Oelsner, Thomas Decker, Christian Meyer zum Büschenfelde, Michaela Wagner, (unknown), (unknown), Burkhard Schmidt, Robert A.J. Oostendorp, Christian Peschel, Ingo Ringshausen	56
13	Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors 2010 ·Annals of Hematology ·Thomas Decker, Christian Bogner, Madlen Oelsner, Christian Peschel, Ingo Ringshausen	19
14	Recruitment of PKC-βII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70 2009 ·Leukemia ·Christian Meyer zum Büschenfelde, Michaela Wagner, (unknown), Madlene Oelsner, (unknown), Thomas Decker, Christian Bogner, Christian Peschel, Ingo Ringshausen	30
15	Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo 2006 ·Cancer Cell ·Ingo Ringshausen, Clodagh C. O’Shea, Andrew J. Finch, Lamorna Brown Swigart, Gérard I. Evan	202
16	The pathological response to DNA damage does not contribute to p53-mediated tumour suppression 2006 ·Nature ·Maria A. Christophorou, Ingo Ringshausen, Andrew J. Finch, Lamorna Brown Swigart, Gérard I. Evan	309
17	Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells 2006 ·Annals of Hematology ·Christian Bogner, Michael Sandherr, (unknown), (unknown), Ingo Ringshausen, Christian Peschel, Thomas Decker	9
18	Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option 2004 ·Leukemia & lymphoma ·Ingo Ringshausen, Christian Peschel, Thomas Decker	23
19	Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells 2004 ·Leukemia ·Ines N. Hahntow, Folker Schneller, Madlene Oelsner, (unknown), Ingo Ringshausen, Falko Fend, Christian Peschel, Thomas Decker	104
20	Cycling B-CLL cells are highly susceptible to inhibition of the proteasome 2003 ·Experimental Hematology ·Christian Bogner, Folker Schneller, Susanne Hipp, Ingo Ringshausen, Christian Peschel, Thomas Decker	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact